TD Cowen downgraded Ginkgo Bioworks Holdings from Buy to Hold and reduced its price target from $12 to $9. This analyst action suggests a revised outlook on the company's future performance and could lead to negative short-term price movement for DNA shares.
TD Cowen analyst Brendan Smith downgraded Ginkgo Bioworks Holdings (DNA) from a 'Buy' rating to a 'Hold' rating and simultaneously lowered the price target from $12 to $9. This action signals a more cautious outlook from a prominent investment bank, likely due to concerns about the company's fundamentals, growth prospects, or valuation. For traders, this is a negative short-term catalyst as it could trigger selling pressure, especially from institutional investors who follow analyst ratings. The reduced price target suggests that TD Cowen sees less upside potential for DNA shares in the near to medium term, impacting investor sentiment and potentially leading to further price depreciation.